Voyager Therapeutics 3Q Loss/Shr 40c >VYGR

Voyager Therapeutics’ collaboration revenue declined year over year in 3Q 2026, while its net loss narrowed. Lower collaboration revenue was partly offset by reduced research and development and general and administrative expenses, reflecting lower VY7523 spending, reduced VY1706 manufacturing cost…